Compare Summit Therapeutics Inc (SMMT) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Summit Therapeutics Inc trades at $15.1 (market cap $12.06B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $73.3. The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SMMT | VEA | |
|---|---|---|
Market Cap | $12.06B | — |
Sector | Health | — |
52-Week High | $26.98 | $72.89 |
52-Week Low | $12.55 | $58.19 |
Enterprise Value | $11.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
VEA trades at $73.30, up 1.1% with a bullish technical signal from moving averages. The ETF shows mixed institutional activity with recent buying from Ferguson Shapiro and selling from Financial Advisory Corp. Technical indicators show overbought RSI conditions while maintaining strong momentum with ADX at 47.42. The fund offers international diversification with a low expense ratio of 0.03% and upcoming dividend payment.
VEA presents a compelling international diversification opportunity with strong technical momentum and cost efficiency. However, overbought conditions and mixed institutional sentiment suggest potential near-term volatility. The fund's focus on developed markets outside the US provides geographic diversification but remains exposed to global economic headwinds and currency fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
